Trial Profile
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALERT-lung; ETOP ALERT-lung
- 01 Oct 2022 Results published in the Lung Cancer
- 09 Apr 2021 Status changed from recruiting to discontinued.
- 05 Apr 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.